Hot Pharma Stocks / Ideen / Blockbuster

  • gefällt mir auch gut BELLUS Health Inc



    (TSE:BLU)

    https://www.google.com/finance…BLU&ei=nq4XUqCbK8qVwQPyRA

    haben eben Thallion Pharmaceuticals Inc.

    (TSE:TLN) https://www.google.com/finance…LN&ei=2rMXUoiPCIWDwAOeggE eingeheimst..

    16% der untigen pipline gehören nun auch Bellus

    http://www.caprion.com/en/in-vitro-diagnostics/pipeline.php

    [Blocked Image: http://www.caprion.com/medias/img/DXpipeline_000.jpg]

    Bellus eigene pipline:

    Products

    The Company’s product portfolio includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.

    BELLUS Health’s primary focus is on advancing KIACTA™, a novel first-in-class treatment for AA amyloidosis through a pivotal Phase III Confirmatory Study that is currently enrolling patients.

    The Company is also developing BLU8499, a prodrug of tramiprosate, intended for the treatment of Alzheimer's disease. BLU8499 is expected to begin a Phase IIa proof of concept study in the second half of 2014.

    VIVIMIND™ is a commercial-stage, cash-flow positive nutraceutical product for memory protection. BELLUS Health has established distribution partnerships for VIVIMIND™ in several countries, including Italy, Canada, Taiwan, Greece, certain countries in the Middle East, Israel and South Korea.

    [Blocked Image: http://www.bellushealth.com/files/pipe_en_1.jpg]

    dazu würde noch die pipeline von Thallion kommen:


    Thallion Pharmaceuticals Inc. is a biotechnology company focused on developing new pharmaceutical products in the areas of infectious disease and oncology. Its product candidates include: Shigamabs, a dual antibody product for the treatment of Shigatoxin-producing E. coli (STEC) bacterial infections and TLN-4601, a proprietary first-in-class small molecule with potential efficacy in multiple oncology indications. The Company also owns technology platform named DECIPHER, a genomics-based discovery platform technology. Its Shigamabs product consists of two monoclonal antibodies designed to bind specifically to Shiga toxin 1 and Shiga toxin 2 secreted by STEC. It has completed four Phase I clinical trials evaluating the safety of Shigamabs.

    das ganze fürne marktkap. von 19 mio !!

  • b00n hat am 14.08.2013 - 17:03 folgendes geschrieben:

    Quote

    Supernus Pharmaceuticals Inc

    (NASDAQ:SUPN) watch

    Supernus Upgraded to Strong Buy

    Why the Upgrade?

    The upgrade came on the back of the U.S. Food & Drug Administration’s (FDA) approval of Trokendi XR for the treatment of epilepsy.

    Trokendi XR is a novel once-daily extended release formulation of Johnson & Johnson's (JNJ - Analyst Report) Topamax (topiramate). This epilepsy product will be launched in a few weeks.

    Along with granting approval, the FDA also agreed to a deferral of submission of post-marketing pediatric pharmacokinetic assessments, which were due in 2019, followed by clinical assessments in 2025. Supernus also got an FDA waiver for certain pediatric study requirements.

    In Jun 2013, Supernus had received tentative approval for Trokendi XR. Trokendi XR had initially received tentative FDA approval in Jun 2012. However, at that time, the FDA had said that final approval depended on the resolution of a marketing exclusivity issue raised by the FDA regarding a specific pediatric population.

    A request for final approval was filed in Dec 2012 along with a safety data update, a new package insert and packaging configurations for Trokendi XR. The FDA had informed Supernus that they will most likely grant this request in the form of a tentative approval because the review period would be expected to conclude within the second quarter, prior to the Jun 22, 2013 expiration of Topamax’ pediatric exclusivity.

  • WARSICS hat am 09.08.2013 - 15:09 folgendes geschrieben:

    Quote

    4.59

    0.00 (0.00%)

    Pre-market: 3.87 -0.72 (-15.69%)

    wochenende versaut. bin offline jetzt. smiley

    see you on monday

    Noch bei DNDN dabei? Mittlerweile haben wir Kurse unter USD 3.00 und die Basher feiern bereits den möglichen Konkurs.


    MK 450mio bei 200mio Cash und 600mio Debt.

  • DNDN

    Aurum hat am 26.08.2013 - 07:00 folgendes geschrieben:

    Quote

    WARSICS hat am 09.08.2013 - 15:09 folgendes geschrieben:

    Noch bei DNDN dabei? Mittlerweile haben wir Kurse unter USD 3.00 und die Basher feiern bereits den möglichen Konkurs.


    MK 450mio bei 200mio Cash und 600mio Debt.

    noch am selben Tag. DNDN hat nichts mehr zu bieten. Sind Geschichte.

  • b00n hat am 16.08.2013 - 16:46 folgendes geschrieben:

    Quote

    Catalyst Pharmaceutical Partners (NASDAQ:CPRX)‘s stock had its “buy” rating reiterated by research analysts at Aegis in a report released on Friday, AR Network reports. They currently have a $3.00 price objective on the stock, up from their previous price objective of $2.50. Aegis’ price objective points to a potential upside of 123.88% from the company’s current price

    wusste gar nicht dass hier buyout rumor im spiel ist..


    Is There Any Substance To The Buyout Rumors Surrounding BioMarin And Catalyst?

    BioMarin Pharmaceutical, Inc. (BMRN) is a fast growing orphan drug developer with the history of a strong appetite for gobbling up small pharma companies with promising pipelines while they are cheap. Always on the lookout for low priced buyout candidates that fit their orphan drug profile, BioMarin now finds itself both the buyer, and the target.

    Ever since October 2012 when it was announced that BioMarin purchased 17% of Catalyst Pharmaceutical Partners, Inc. (CPRX), buyout rumors have been circulating about BioMarin making an offer for the balance of the company. Is Catalyst a good fit? If so, what will the buyout price be? When will the offer be made? On the other side of the fence, BioMarin shareholders are asking the same questions about their company if a larger company makes a bid for them as rumors are suggesting.

  • b00n hat am 22.07.2013 - 16:46 folgendes geschrieben:

    BioCryst Pharmaceuticals Now Covered by Wells Fargo & Co.

  • b00n hat am 15.08.2013 - 17:32 folgendes geschrieben:






    YEA habe party, VOLLTREFFER :) Pre-market: 2.25 +0.83 (58.45%)



    Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation From FDA for Firdapse(TM) for the Treatment of LEMS

    http://www.globenewswire.com/n…he-Treatment-of-LEMS.html

  • 2brix hat am 26.08.2013 - 19:14 folgendes geschrieben:

    Quote

    WARSICS hat am 26.08.2013 - 12:59 folgendes geschrieben:

    wieso meinst du?


    Die haben doch noch das Medikament Provenge in der Pipeline...

    nee, das ist schon raus aus der pipeline. und namentlich auch ein richtiger rohrkrepierer.


    seit wir die verfolgen, galt mal 1,3 mrd. (yepp, MILLIARDEN) als umsatzziel im 2013... schlappe 350 mio. hat's gebracht. 2014 gibt es evtl mal 400 mio.


    vom kostenpunkt für die superwaffe provenge bewegt man sich wohl um die 2 mrd. USD. have fun guys, getting rid of that debt. ohne mich.

  • WARSICS hat am 27.08.2013 - 17:47 folgendes geschrieben:

    Richtig DNDN kann Bankrott gehen, die Chance ist auch sehr hoch ABER das letzte Wort ist hier noch nicht gesprochen.

    Panik und Euphorie können sehr schnell die Seiten wechseln z.b
    - Wenn Provenge eine EU Zulassung bekommt und diese verpartnert
    - Sequencing Daten von Provenge zusammen mit Zytiga (Johnson & Johnson) sowie in ADT werden 2013 noch kommen
    - Eine Sequencing Xtandi (Medivation) PII will DNDN dieses Jahr noch starten
    - Eine andere Entwicklung (DN24-02, APC 8015 usw.) verpartnert wird
    - Ein Investor oder HF hier investiert weil das Potential von Immuntherapien noch lange nicht ausgeschöpft ist
    - Plötzlich 1-2 BP sich um DNDN (vor allem deren Immuntherapien Plattform) streiten = hochbieten
    - Der bisher nutzlose CEO (Kursentwicklung ich glaube seit Antritt von USD 17.00 auf USD 2.78) welcher von der Shorts gefeiert
    wird abtritt.

    = Eine positive News bei mehr als 50Mio Shorts und die Kurs springt nach Norden.

    Denke dennoch eine KE wird unumgänglich sein, hier sehe ich die Chance das es im Interesse von DNDN ist den Kurs nochmals ordentlich nach oben zu pushen um dann ordentlich neues Geld zu beschaffen. Eine KE zu 3.50 bringt z.B 200Mio mehr in die Kasse als eine zu USD 1.50 wenn wir von 100mio neuen Aktien ausgehen.

    Die nächsten Wochen werden spannend.

  • b00n hat am 23.08.2013 - 20:44 folgendes geschrieben:



    $2 Biotech Could be the Best Chance to Triple Your Money in This Market

    One biotech stock that has bucked this summer's fear-driven sell-offs is Idera Pharmaceuticals (IDRA). Shares have rocketed over 300% since the beginning of May, rising from just over $0.50 to a 52-week high of $2.13 last week. Compare this performance to the lackluster overall market during this time frame and it paints a compelling picture for this little biotech stock.

    Idera Pharmaceuticals is a clinical-stage biotechnology company that was founded in 1989. It specializes in the discovery and development of novel synthetic DNA- and RNA-based drugs. These drugs are targeted to treat autoimmune and inflammatory diseases, primarily psoriasis, lupus, asthma, allergies and different forms of cancer. The company has zero debt on the balance sheet and an enterprise value of $73 million.


    In July, the company announced that it received a U.S. patent on its IMO-8400 drug, protecting both the composition and method of use. The product is the company's lead contender for the treatment of autoimmune diseases, and it is currently being evaluated in a Phase II trial in patients with moderate-to-severe plaque psoriasis.


    As in the case with most early stage biotech companies, IDRA has no earnings and incurs high expenses in the attempt to get products to market. But the company raised $16.5 million during the second quarter through a common stock offering. With cash and cash equivalents of $16.3 million, the company said it is confident it can complete the Phase II trials by the first quarter of 2014 and fund operations through the end of that year. This is a major positive for the stock.


    Another substantial positive is that the recently appointed chairman of the board of directors, James Geraghty, purchased 300,000 shares at $1.75 for a total of $525,000.


    Technically, IDRA looks like a screaming buy right now. The uptrend has been in full effect since May 1. Traders may want to wait for an intraday pullback or enter on upward momentum depending on their preferred method of trading.

    [Blocked Image: http://l.yimg.com/bt/api/res/1.2/JlI_vvVQF5tc5qZ8Ct_ALQ--/YXBwaWQ9eW5ld3M7cT04NTt3PTYwMA--/http://globalfinance.zenfs.com/en_us/Finance/US_AHTTP_STREET_AUTHORITY_HOS_LIVE/08-27-13-idra.PNG]


    Recommended Trade Setup:


    -- Buy IDRA on a pullback to $2 or a breakout above $2.25
    -- Set stop-loss at $1.70
    -- Set initial price target at $6 for a potential 167%-200% gain in nine months


    http://finance.yahoo.com/news/…est-chance-214500617.html

  • NF ENERGY SAVING ORD (NFEC) Kursziel von 1.85 auf 12.50

    Kursziel 12.50$


    Kurs am 28.8.13 1.85$


    http://finance.yahoo.com/q?s=NFEC&ql=0



    NF Energy Saving Corporation (NFEC), is engaged in manufacturing large diameter energy efficient flow control systems for thermal and nuclear power generation plants, major national and regional water supply projects and municipal water, gas and heat supply pipeline networks, and energy saving technology consulting, optimization design services, energy saving reconstruction of pipeline networks and contractual energy management services for China's electric power, petrochemical, coal, metallurgy, construction, and municipal infrastructure industries. In August 2013, NF Energy Saving Corporation established a new subsidiary, NF Energy Corporation Guangdong Subsidiary in Guangzhou, China.

    http://www.nfenergy.com

  • b00n hat am 27.08.2013 - 15:53 folgendes geschrieben:

    Quote

    Catalyst Pharmaceutical Partners Price Target Raised to $3.50 at Aegis (CPRX)


    on Aug 27th, 2013

    H.C. Wainwright initiates coverage on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) with a Buy. PT $5.00.


    :)

  • Hi b00n, hi @all


    Mich würde mal interessieren, wie du die ganze Marijuana Geschichte in der USA siehst? Wenn das einigen Staaten legal ist, gibts da ja vermutlich schon noch einiges an Umsatz :D


    EDXC bin ich schon länger am beobachten, aber noch nie eingestiegen, da andere Projekte ;)


    MJNA hatte ich mal auf dem Radar, aber wieder verloren



    Gruss


    2b